X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare GSK Pharma with Pfizer - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GSK PHARMA vs PFIZER - Comparison Results

GSK PHARMA    Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

PFIZER 
   Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GSK PHARMA PFIZER GSK PHARMA/
PFIZER
 
P/E (TTM) x 66.5 32.9 202.0% View Chart
P/BV x 11.7 4.9 238.0% View Chart
Dividend Yield % 1.1 0.8 140.7%  

Financials

 GSK PHARMA   PFIZER
EQUITY SHARE DATA
    GSK PHARMA
Mar-17
PFIZER
Mar-17
GSK PHARMA/
PFIZER
5-Yr Chart
Click to enlarge
High Rs3,8382,055 186.8%   
Low Rs2,6371,651 159.7%   
Sales per share (Unadj.) Rs354.2429.8 82.4%  
Earnings per share (Unadj.) Rs39.873.6 54.0%  
Cash flow per share (Unadj.) Rs42.987.4 49.1%  
Dividends per share (Unadj.) Rs30.0020.00 150.0%  
Dividend yield (eoy) %0.91.1 85.9%  
Book value per share (Unadj.) Rs236.9528.7 44.8%  
Shares outstanding (eoy) m84.7045.75 185.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x9.14.3 212.0%   
Avg P/E ratio x81.425.2 323.4%  
P/CF ratio (eoy) x75.521.2 356.1%  
Price / Book Value ratio x13.73.5 389.9%  
Dividend payout %75.427.2 277.7%   
Avg Mkt Cap Rs m274,21684,777 323.5%   
No. of employees `0004.72.8 165.4%   
Total wages/salary Rs m4,8303,039 158.9%   
Avg. sales/employee Rs Th6,387.06,925.9 92.2%   
Avg. wages/employee Rs Th1,028.31,070.4 96.1%   
Avg. net profit/employee Rs Th717.11,186.3 60.4%   
INCOME DATA
Net Sales Rs m30,00019,663 152.6%  
Other income Rs m7281,012 72.0%   
Total revenues Rs m30,72820,674 148.6%   
Gross profit Rs m4,1903,491 120.0%  
Depreciation Rs m263629 41.8%   
Interest Rs m010 0.0%   
Profit before tax Rs m4,6553,864 120.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m4571,304 35.0%   
Tax Rs m1,7441,801 96.9%   
Profit after tax Rs m3,3683,368 100.0%  
Gross profit margin %14.017.8 78.7%  
Effective tax rate %37.546.6 80.4%   
Net profit margin %11.217.1 65.5%  
BALANCE SHEET DATA
Current assets Rs m16,74220,789 80.5%   
Current liabilities Rs m7,2027,870 91.5%   
Net working cap to sales %31.865.7 48.4%  
Current ratio x2.32.6 88.0%  
Inventory Days Days5260 86.7%  
Debtors Days Days2122 92.7%  
Net fixed assets Rs m8,6359,175 94.1%   
Share capital Rs m847458 185.1%   
"Free" reserves Rs m19,22223,731 81.0%   
Net worth Rs m20,06924,189 83.0%   
Long term debt Rs m1025 40.0%   
Total assets Rs m30,03832,706 91.8%  
Interest coverage xNM403.5-  
Debt to equity ratio x00 48.2%  
Sales to assets ratio x1.00.6 166.1%   
Return on assets %11.210.3 108.6%  
Return on equity %16.813.9 120.5%  
Return on capital %25.521.4 119.1%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m52863 839.4%   
Fx outflow Rs m7,1934,067 176.9%   
Net fx Rs m-6,665-4,004 166.5%   
CASH FLOW
From Operations Rs m2,3603,288 71.8%  
From Investments Rs m3,008-2,496 -120.5%  
From Financial Activity Rs m-5,108-826 618.4%  
Net Cashflow Rs m260-35 -752.3%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 50.7 63.9 79.3%  
Indian inst/Mut Fund % 10.2 7.5 136.0%  
FIIs % 23.8 4.9 485.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 15.4 23.7 65.0%  
Shareholders   102,036 85,207 119.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GSK PHARMA With:   ALEMBIC PHARMA  STRIDES SHASUN LTD  FDC LTD.  ASTRAZENECA PHARMA  DISHMAN PHARMA  

Compare GSK PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Flat; Metal Stocks Drag(09:30 am)

Asian share markets slipped in the opening trade today as investors digested the escalation in trade tensions between the US and China after both countries announced tariffs last week.

Related Views on News

GSK PHARMA Announces Quarterly Results (4QFY18); Net Profit Down 6.4%

May 28, 2018 | Updated on May 28, 2018

For the quarter ended March 2018, GSK PHARMA has posted a net profit of Rs 1 bn (down 6.4% YoY). Sales on the other hand came in at Rs 7 bn (down 4.5% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

After Vakrangee and Manpasand, More Auditors May Soon Resign. To Protect Your Wealth, Avoid these Stocks(The 5 Minute Wrapup)

Jun 8, 2018

The change in auditing regulations can bring a big change in corporate governance behaviour in the mid and small-cap space.

Should You Get out of Small Caps Now... Before the Fall Worsens(Profit Hunter)

Jun 6, 2018

An almost zero-loss strategy that works best when markets correct. Don't let the current volatility overwhelm you. Focus on the fundamentals and long term, and buy stocks where quality meets value.

Why Bank-Mergers Continue to Remain a Bad Idea(Vivek Kaul's Diary)

Jun 5, 2018

A newsreport suggests that the government plans to merge four public sector banks. We think it's a bad idea.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Is Data Pointing Towards a Revival in the FMCG Sector?(Sector Info)

Jun 8, 2018

After several quarters of stress in the aftermath of demonetisation and the rollout of GST, this data is pointing towards revival in the India's rural FMCG industry.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GSK PHARMA SHARE PRICE


Jun 18, 2018 11:35 AM

TRACK GSK PHARMA

  • Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

GSK PHARMA - J.B.CHEMICALS COMPARISON

COMPARE GSK PHARMA WITH

MARKET STATS